GlassScriptPhysician profile
Libu Varughese
NPI 1053750331
$13,837.51
in general payments reported to CMS, 2019-2025
49 companies · $4,503 in 2025
The $4,503 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $657 · 2021: $1,365 · 2022: $1,476 · 2023: $2,163 · 2024: $3,416 · 2025: $4,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,806 · Gift: $178 · Education: $73.79 · Entertainment: $16.71 · Travel and Lodging: $6.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,806.08 |
| Gift | $178.20 |
| Education | $73.79 |
| Entertainment | $16.71 |
| Travel and Lodging | $6.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $1,259.08 | 2024-2025 | Omnipod, Omnipod |
| Novo Nordisk INC | $1,245.13 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $1,159.11 | 2020-2025 | Afrezza |
| Corcept Therapeutics | $1,032.13 | 2020-2025 | Korlym |
| Lilly USA, LLC | $1,012.96 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $949.65 | 2019-2025 | Tepezza, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $796.97 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.78 | 2020-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $507.08 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $486.75 | 2019-2024 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $373.56 | 2022-2025 | Strensiq |
| Abbott Laboratories | $348.33 | 2022-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Xeris Pharmaceuticals, INC. | $337.78 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $304.34 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Dexcom, INC. | $290.79 | 2021-2025 | Dexcom G6 Transmitter |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $287.48 | 2023-2025 | Yorvipath |
| Abbvie INC. | $270.70 | 2022-2025 | Synthroid |
| Recordati_rare_diseases_inc. | $267.89 | 2021-2025 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $246.95 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $205.37 | 2020-2025 | Tymlos |
| Cequr Corporation | $199.83 | 2022-2025 | Cequr Simplicity |
| Horizon Therapeutics Plc | $192.41 | 2021-2023 | Tepezza |
| Madrigal Pharmaceuticals | $190.86 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $177.09 | 2023-2025 | |
| Embecta Corp. | $156.69 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Neurocrine Biosciences, INC. | $151.49 | 2025 | |
| Ibsa Pharma INC. | $85.43 | 2021-2024 | Licart, Tirosint, Tirosint |
| Kyowa Kirin, INC. | $82.77 | 2024-2025 | Crysvita |
| Avvisto Therapeutics, LLC | $66.71 | 2025 | Cycloset |
| Acella Pharmaceuticals, LLC | $55.87 | 2024-2025 | NP Thyroid 60 |
| Nevro Corp. | $55.85 | 2023 | Senza |
| Pfizer INC. | $47.53 | 2022-2024 | |
| Tolmar, INC. | $41.01 | 2025 | Jatenzo |
| Ultragenyx Pharmaceutical INC. | $39.52 | 2023-2024 | Crysvita, Crysvita |
| Janssen Pharmaceuticals, INC | $36.56 | 2020 | |
| Amneal Pharmaceuticals LLC | $33.60 | 2021-2022 | |
| Sandoz INC. | $26.62 | 2025 | |
| Eusa Pharma (US) LLC | $26.06 | 2022 | |
| Globus Medical, INC. | $24.43 | 2025 | Senza |
| Glaxosmithkline, LLC. | $22.86 | 2025 | Shingrix |
| Theracosbio, LLC | $22.63 | 2024 | Brenzavvy |
| Ipsen Biopharmaceuticals, INC | $18.33 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.11 | 2022 | |
| Currax Pharmaceuticals LLC | $17.82 | 2025 | Contrave |
| Sequel Med Tech, LLC | $16.85 | 2025 | Twiist |
| Optos, INC. | $16.71 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Evoke Pharma, INC. | $15.62 | 2025 | |
| Grt US Holding, INC. | $14.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libu Varughese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.